ImmunityBio Inc (IBRX)

In January 2026, ImmunityBio announced positive results from its ANKTIVA clinical program in NSCLC trials, leading to a surge in the stock price. In December 2025, the EMA issued a positive recommendation for conditional marketing authorization of ANKTIVA for BCG-unresponsive NMIBC, marking a significant step towards expanding market access in Europe. In November 2025, the company reported strong financial results for Q3 2025, with product revenue increasing by 434% year-over-year, primarily driven by ANKTIVA sales. In July 2025, ImmunityBio announced preliminary Q2 2025 financial results, showing a 60% increase in revenue from Q1 2025 and a 246% increase in ANKTIVA unit sales volume since the J-code approval. In May 2025, the FDA issued a "Refuse-to-File" notice for a supplemental Biologics License Application (sBLA) for papillary-only NMIBC, indicating a requirement for a randomized controlled trial. In January 2025, the award of a permanent J-code for ANKTIVA significantly contributed to increased sales momentum and unit sales growth throughout the year.

Given the nature of ImmunityBio's products, demand is not typically subject to traditional seasonal fluctuations. The consistent reporting of strong sales momentum and unit growth for ANKTIVA suggests a steady and increasing demand driven by medical need rather than seasonal patterns.

ImmunityBio, Inc. is a clinical-stage biotechnology company focused on developing next-generation immunotherapies for cancer and infectious diseases. The company operates within the Healthcare sector, specifically in the Biotechnology and Pharmaceutical Products industries. Its primary product is ANKTIVA, an FDA-approved IL-15 superagonist immunotherapy used in combination with Bacillus Calmette-Guérin (BCG) for the treatment of adult patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ, with or without papillary tumors. ANKTIVA is also being investigated in clinical trials for other solid tumors, including non-small cell lung cancer (NSCLC), and for infectious diseases like HIV and SARS-CoV-2. The company's pipeline also includes various off-the-shelf, allogeneic cell therapies and combination therapies designed to overcome tumor resistance.

ImmunityBio's operations are primarily concentrated in the United States and Europe, with the majority of its revenue generated from the U.S. The company conducts preclinical research and clinical trials across North America, Europe, and Australia, with plans for further filings in Canada and Asia.

ImmunityBio's brand reputation has been positively impacted by the FDA and UK MHRA approval of ANKTIVA for bladder cancer treatment. The positive clinical trial results for ANKTIVA in lung cancer and the EMA's positive recommendation for bladder cancer therapy further enhance its reputation. The significant year-over-year product revenue growth for ANKTIVA also indicates strong market acceptance and physician adoption. While the FDA's "Refuse-to-File" decision for papillary-only NMIBC could be seen as a setback, the company's ongoing engagement with the agency to address the requirements demonstrates its commitment to advancing its pipeline.

ImmunityBio's ownership structure is a mix of institutional, retail, and individual investors. Dr. Patrick Soon-Shiong is the largest individual shareholder, holding a significant majority of the company's shares. Major institutional owners include Vanguard Group Inc, BlackRock, Inc., Jane Street Group, Llc, State Street Corp, Geode Capital Management, Llc, Heights Capital Management, Inc, Woodline Partners LP, and Morgan Stanley. Institutional investors collectively hold between 11.74% and 14.52% of the company's stock, while retail investors also hold a substantial portion.